FarmaKology Newsletter - Issue #7
23andMe is the leading consumer genetics and research company. We are a web-based service that helps you understand what your DNA says about your health, traits and ancestry. After providing a saliva sample using an at-home kit, you can learn how your genetics may influence your health, discover where your DNA is from out of 31 populations worldwide - and more.
The U.S. Food and Drug Administration today permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS) System, is indicated for patients ages 7 to12 years old who are not currently taking prescription ADHD medication and is the first non-drug treatment for ADHD granted marketing authorization by the FDA.
IBM announced recently that it is discontinuing the development and sales of its Watson for Drug Discovery product. Poor financial performance is to blame for the discontinuation, IBM says. The company will continue to support existing clients, but will not be taking any new clients.
Salford Royal NHS Foundation Trust in England is expanding an initiative to use robot technology for improving administration of medicines after a trial started on the Pendleton Suite before the end of last year indicated it could free up time for staff.
PerkinElmer has signed on to Accenture’s life science partner ecosystem and will integrate its big data technology and content into the cloud-based platform’s wider efforts in drug discovery and research.
Research & Study
Listen to Are Drug Interaction Warnings Influenced By Drug Company Promotion? An Interview With Dr. Jeffery Mattes and 16 other episodes by Psychopharmacology And Psychiatry Updates. No signup or install required.